220 related articles for article (PubMed ID: 35622315)
21. Certolizumab pegol in the treatment of psoriasis: Real-life data.
Turkmen M; Dogan S
Dermatol Ther; 2021 May; 34(3):e14929. PubMed ID: 33665940
[TBL] [Abstract][Full Text] [Related]
22. Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J).
Honma M; Cai Z; Burge R; Zhu B; Yotsukura S; Torisu-Itakura H
Dermatol Ther (Heidelb); 2020 Dec; 10(6):1397-1404. PubMed ID: 32910360
[TBL] [Abstract][Full Text] [Related]
23. [Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Ruiz AN; Alberola FT; Aceituno S;
Farm Hosp; 2024; 48(2):T51-T56. PubMed ID: 38148255
[TBL] [Abstract][Full Text] [Related]
24. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
Suleiman AA; Khatri A; Oberoi RK; Othman AA
Clin Pharmacokinet; 2020 May; 59(5):575-589. PubMed ID: 31667790
[TBL] [Abstract][Full Text] [Related]
25. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
26. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
Blauvelt A; Reich K; Lebwohl M; Burge D; Arendt C; Peterson L; Drew J; Rolleri R; Gottlieb AB
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):546-552. PubMed ID: 30242918
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study.
Yamasaki K; Nakagawa H; Kubo Y; Ootaki K;
Br J Dermatol; 2017 Mar; 176(3):741-751. PubMed ID: 27106510
[TBL] [Abstract][Full Text] [Related]
28. Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol.
Navarro Ruiz A; Toledo Alberola F; Aceituno S;
Farm Hosp; 2024; 48(2):51-56. PubMed ID: 37739901
[TBL] [Abstract][Full Text] [Related]
29. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
Seo SJ; Shin BS; Lee JH; Jeong H
J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
[TBL] [Abstract][Full Text] [Related]
31. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.
Mease P; Deodhar A; Fleischmann R; Wollenhaupt J; Gladman D; Leszczyński P; Vitek P; Turkiewicz A; Khraishi M; FitzGerald O; Landewé R; de Longueville M; Hoepken B; Peterson L; van der Heijde D
RMD Open; 2015; 1(1):e000119. PubMed ID: 26509074
[TBL] [Abstract][Full Text] [Related]
32. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
[TBL] [Abstract][Full Text] [Related]
38. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
Gottlieb AB; Blauvelt A; Thaçi D; Leonardi CL; Poulin Y; Drew J; Peterson L; Arendt C; Burge D; Reich K
J Am Acad Dermatol; 2018 Aug; 79(2):302-314.e6. PubMed ID: 29660421
[TBL] [Abstract][Full Text] [Related]
39. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.
van der Heijde D; Deodhar A; FitzGerald O; Fleischmann R; Gladman D; Gottlieb AB; Hoepken B; Bauer L; Irvin-Sellers O; Khraishi M; Peterson L; Turkiewicz A; Wollenhaupt J; Mease PJ
RMD Open; 2018; 4(1):e000582. PubMed ID: 29556416
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report.
Lu X; Wang W
Clin Cosmet Investig Dermatol; 2023; 16():1977-1981. PubMed ID: 37539023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]